Phase 1b Trial – Talk Bio

ProMIS Neurosciences Announces New Peer-Reviewed Publication Highlighting Selective Targeting of Toxic Oligomers for Potential Clinical Benefit and Reduced ARIA Risk

8 hours ago talkbio0Tagged ARIA risk, Binding action, Biological Markers, clinical outcomes, Dental Plaque, oligomer selectivity, Phase 1b Trial, PMN310, PRECISE-AD trial, ProMIS Neurosciences, Toxic Oligomers, vascular deposit binding

ProMIS Neurosciences; PMN310; toxic oligomers; ARIA risk; PRECISE-AD trial; peer-reviewed publication; oligomer selectivity; plaque binding; vascular deposit binding; phase 1b trial; biomarkers; clinical outcomes

ADC Therapeutics to Provide Update on LOTIS-7 Clinical Trial on December 3, 2025

1 week ago talkbio0Tagged clinical trial update, Corporate, Effectiveness, loncastuximab tesirine, LOTIS-7, Phase 1b Trial, Safety, therapeutic autologous dendritic cells, Zynlonta

ADC Therapeutics; LOTIS-7; clinical trial update; ZYNLONTA; Phase 1b trial; loncastuximab tesirine; safety; efficacy; corporate webcast

FDA Lifts Clinical Hold on Entrada’s Duchenne Muscular Dystrophy Drug ENTR-601-44 After Two Years

10 months ago talkbio0Tagged ELEVATE-44, ENTR-601, Entrada, exon, Muscular Dystrophy, Duchenne, Phase 1b Trial, skipping, Study on Hold, United States Food and Drug Administration

Duchenne muscular dystrophy, ENTR-601-44, Entrada Therapeutics, FDA, clinical hold, exon 44 skipping, ELEVATE-44-102, Phase 1b trial

Zealand Pharma’s GLP-1/GLP-2 Receptor Dual Agonist Shows Promising Weight Loss in Phase 1b Trial

1 year ago talkbio0Tagged GLP-1/GLP-2 receptor, Obesity, Phase 1b Trial, Zealand Pharma

Zealand Pharma, GLP-1/GLP-2 receptor dual agonist, dapiglutide, obesity, weight loss, Phase 1b trial